James Spain, MD
Sports Medicine · Daphne, ALNPI 1477714889
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $18,757 of the $22,253 with a category attached, or 84.3%. Arthrex accounts for 96.1% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2019 at $16,734 and has fallen 98.2% since, to $309 in 2025.
Across 63 payments — averaging $353.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Arthrex$21K
- Pacira Pharmaceuticals Incorporated$222
- DJO, LLC$186
- Smith+Nephew$151
- Sanofi$142
- Amgen$96
- plus $79 from 4 others
What the payments were for
- Speaking & faculty fees$18,75784%
- Travel & lodging$2,26310%
- Food & beverage$1,2336%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Arthrex | 42 | $21,377 |
| Pacira Pharmaceuticals Incorporated | 4 | $222 |
| DJO, LLC | 10 | $186 |
| Smith+Nephew | 1 | $151 |
| Sanofi | 1 | $142 |
| Amgen | 1 | $96 |
| Si-bone, Inc. | 1 | $24 |
| Lilly USA, LLC | 1 | $19 |
| Trice Medical, Inc. | 1 | $19 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,253 in reported general payments places this provider in the 75th percentile of 108 sports medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 106 | $2,002 |
| Cyclobenzaprine Hcl | 61 | $286 |
| Methylprednisolone | 29 | $231 |
| Nitroglycerin PatchNitroglycerin | 12 | $220 |
| Gabapentin | 42 | $179 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 16 | $95 |
| Tramadol Hcl | 23 | $61 |
| Meloxicam | 17 | $27 |
Paid to pharmacies, not to this prescriber.
Other sports medicine in Daphne
- Daniel MatthewsDaphne$190K
- Edward CainBirmingham$12.7M
- Mark RogersBirmingham$94K
- Amit MomayaBirmingham$77K
- Matthew SmithGuntersville$73K
- Christoper GarrettBirmingham$58K
- Jonathan IsbellHoover$55K
- James McMurtrieHuntsville$54K
- Reaves CrabtreeBirmingham$47K
- David AdkisonBirmingham$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.